

***Amendments to the Claims***

This listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-144 (canceled).

Claim 145 (New).     An isolated polypeptide comprising amino acids -51 to 133 of SEQ ID NO:2.

Claim 146 (New).     The polypeptide of claim 145 which comprises amino acids -51 to 360 of SEQ ID NO:2.

Claim 147 (New).     The polypeptide of claim 145, wherein said polypeptide binds TRAIL.

Claim 148 (New).     The polypeptide of claim 145, wherein said polypeptide induces apoptosis.

Claim 149 (New).     The polypeptide of claim 145, which is produced by a recombinant host cell.

Claim 150 (New).     The polypeptide of claim 149, wherein said recombinant host cell is a eukaryotic cell.

Claim 151 (New). The polypeptide of claim 145, further comprising a heterologous polypeptide.

Claim 152 (New). The polypeptide of claim 151, wherein said heterologous polypeptide comprises an immunoglobulin Fc region.

Claim 153 (New). The polypeptide of claim 152, wherein said immunoglobulin Fc region is a human immunoglobulin Fc region.

Claim 154 (New). A pharmaceutical composition comprising the polypeptide of claim 145 and a carrier.

Claim 155 (New). An isolated polypeptide comprising amino acids 1-360 of SEQ ID NO:2.

Claim 156 (New). The polypeptide of claim 155, wherein said polypeptide binds TRAIL.

Claim 157 (New). The polypeptide of claim 155, wherein said polypeptide induces apoptosis.

Claim 158 (New). The polypeptide of claim 155, which is produced by a recombinant host cell.

Claim 159 (New). The polypeptide of claim 158, wherein said recombinant host cell is a eukaryotic cell.

Claim 160 (New). The polypeptide of claim 155, further comprising a heterologous polypeptide.

Claim 161 (New). The polypeptide of claim 160, wherein said heterologous polypeptide comprises an immunoglobulin Fc region.

Claim 162 (New). The polypeptide of claim 161, wherein said immunoglobulin Fc region is a human immunoglobulin Fc region.

Claim 163 (New). A pharmaceutical composition comprising the polypeptide of claim 155 and a carrier.

Claim 164 (New). An isolated polypeptide, which comprises at least 30 contiguous amino acids of SEQ ID NO:2.

Claim 165 (New). The polypeptide of claim 164, comprising at least 50 contiguous amino acids of SEQ ID NO:2.

Claim 166 (New). The polypeptide of claim 164, further comprising a heterologous polypeptide.

Claim 167 (New). The polypeptide of claim 166, wherein said heterologous polypeptide comprises an immunoglobulin Fc region.

Claim 168 (New). The polypeptide of claim 167, wherein said immunoglobulin Fc region is a human immunoglobulin Fc region.

Claim 169 (New). A pharmaceutical composition comprising the polypeptide of claim 164 and a carrier.